Page 102 - 2019_10 resto del Mondo_web

I. Tsuboi et al.
A
B
Figure 2. Repeated lipopolysaccharide treatment induced hepatosplenomegaly in SAMP/TA-1 mice. (A) Changes in the ratio of liver and spleen weight to total body weight (BW) in SAMR1 and SAMP1/TA-1 mice after treatment with lipopolysaccharide (LPS). Changes in the ratio of liver (a) and spleen weight (b) to total BW in SAMR1 and SAMP1/TA-1 mice after repeated LPS treatment are shown. The samples of spleen and liver obtained from non-treated control mice (day 0) and mice 7, 14, and 21 days after the first treatment with 25 μg LPS were weighed and expressed as a ratio of liver and spleen weight to total BW. Each bar represents the mean ± standard deviation obtained from three mice. (B) Photograph of spleen and liver specimens from SAMP1/TA-1 mice 21 days after the first treatment with saline or 25 μg LPS.
Lipopolysaccharide treatment induced hypofibrinogenemia and hyperferritinemia in SAMP1/TA-1 mice
The levels of fibrinogen in plasma in SAMP1/TA-1 mice 7 days after the first treatment with saline or LPS were 241 ± 55 mg/dL and 103 ± 13 mg/dL, respectively (Figure 5A). The levels of fibrinogen in the plasma of other strains of mice range from 200 to 400 mg/dL.25 The levels of ferritin in serum in SAMP1/TA-1 mice 21 days after the first treat- ment with saline or LPS were 1680 ± 138 ng/mL and 3080 ± 1126 ng/mL, respectively (Figure 5B). The levels of fer- ritin in the serum of other strains of mice range from 750 to 1000 ng/mL.26,27
Numerical changes in hematopoietic progenitor cells in bone marrow from SAMR1 and SAMP1/TA-1 mice after repeated lipopolysaccharide treatment
The numbers of hematopoietic progenitor cells in femoral bone marrow were evaluated in SAMR1 and SAMP1/TA-1 mice after repeated LPS treatment (Figure 6).
The numbers of myeloid progenitor (CFU-GM) cells in both SAMR1 and SAMP1/TA-1 mice on days 7, 14, and 21 after the first LPS treatment were similar to those in the non-treated control group (day 0).
The numbers of B-cell progenitor (CFU-preB) cells in SAMR1 mice on days 7, 14, and 21 after the first LPS treat-
ment were slightly decreased compared with those of the non-treated control group. In contrast, the numbers of CFU- preB cells in SAMP1/TA-1 mice on days 7, 14, and 21 after the first LPS treatment were significantly decreased com- pared with those of the non-treated control group.
The numbers of erythroid progenitor (BFU-E) cells in both SAMR1 and SAMP1/TA-1 mice on days 7, 14, and 21 after the first LPS treatment were decreased compared with those of the non-treated control group. The magnitude of the decrease in the number of BFU-E cells was greater in SAMP1/TA-1 mice than in SAMR1 mice (day 7; SAMR1 vs. SAMP1/TA-1 P<0.05, day 14; SAMR1 vs. SAMP1/TA-1 P<0.05, day 21; SAMR1 vs. SAMP1/TA-1 P<0.05).
The numbers of megakaryocytic progenitor (CFU-Mk) cells in SAMP1/TA-1 mice on days 7, 14, and 21 after the first LPS treatment were decreased compared with those of the non-treated control group, whereas the numbers of CFU-Mk cells in SAMR1 mice on days 7, 14, and 21 after the first LPS treatment were increased.
Changes in the levels of gene expression of cytokines and chemokines in the liver and spleen in SAMR1 and SAMP1/TA-1 mice after the first lipopolysaccharide treatment
Levels of gene expression of inflammatory cytokines, such as IL-1β, IL-6, TNF-α, and IFN-g, anti-inflammatory
1998
haematologica | 2019; 104(10)